Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:

NCT ID: NCT06178549 Recruiting - Clinical trials for Cervical Cancer Screening

Emergency Room HPV Self-Sampling Study (ACT NOW)

ACT NOW
Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to develop and evaluate an evidence-based public health intervention using HPV self-sampling approach in an opportunistic setting to increase cervical cancer screening among screening non-attendees, particularly those uninsured or underinsured, who use emergency services to access medical care. The proposed pilot study will examine the feasibility and efficacy of HPV self-sampling among women at a safety net hospital emergency room. Participant recruitment and self-sample will take place in the waiting rooms in the ER. All women sitting in the waiting room will serve as the source population for the study and will be approached and invited to participate in the study.

NCT ID: NCT06172478 Recruiting - Prostate Cancer Clinical Trials

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Start date: February 26, 2024
Phase: Phase 2
Study type: Interventional

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.

NCT ID: NCT06166420 Recruiting - Cervical Cancer Clinical Trials

Home-based Cervical Cancer Screening Project

CASAHO
Start date: March 27, 2023
Phase: N/A
Study type: Interventional

Cervical cancer is a public health problem in Cameroon.In 2020, the country had a crude incidence of 20.2 per 100 000 women for an incidence to mortality ratio of 0.65. As for now, the country does not have a national screening program to combat the disease. Only 6% of cameroonian women have once been screened for cervical cancer. In order to increase screening uptake so as to reach 70% recommended by the World Health Organization (WHO), a home-based cervical cancer screening approach is proposed. The objective of our study is to compare two recruitment strategies for cervical cancer screening in rural Cameroon.

NCT ID: NCT06165614 Recruiting - Cervix Cancer Clinical Trials

Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

Start date: March 4, 2024
Phase: Phase 1
Study type: Interventional

To investigate the use of self-administered artesunate vaginal pessaries as treatment for cervical precancer in low and middle-income countries (LMIC). The central hypothesis of this study is that self-administered intravaginal Artesunate will be safe, and result in a clinical response among both HIV-positive and HIV-negative women with cervical precancer in LMICs.

NCT ID: NCT06157151 Recruiting - Cervical Cancer Clinical Trials

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.

NCT ID: NCT06156514 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

MICHELE
Start date: November 6, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this phase III clinical trial, is to evaluate the efficacy and safety of concomitant chemo-radiotherapy with Cisplatin vs Gemcitabine as the first line of treatment in patients with locally advanced cervical cancer, with comorbidities and preserved renal function.

NCT ID: NCT06155396 Recruiting - Cervical Cancer Clinical Trials

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Start date: January 11, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer

NCT ID: NCT06149598 Recruiting - Cervical Cancer Clinical Trials

Coughing at Time of Cervical Biopsy

Start date: January 2, 2024
Phase: N/A
Study type: Interventional

To investigate the effect of coughing as an intervention to reduce pain in colposcopy guided biopsy.

NCT ID: NCT06142760 Recruiting - Cervical Cancer Clinical Trials

MR-guidance in Chemoradiotherapy for Cervical Cancer

AIM-C1
Start date: November 15, 2023
Phase: N/A
Study type: Interventional

Concurrent chemoradiotherapy (CCRT), consisting of external beam radiotherapy (EBRT) and chemotherapy, followed by brachytherapy (BT) is the standard of care for patients with locally advanced cervical carcinoma. In current clinical practice, conventionally, one radiotherapy plan based on the initial planning computed tomography (CT) and magnetic resonance imaging (MRI) scan of the pelvis is applied for the complete 5-6 weeks of EBRT. However, there is a high degree of cervix and uterus motion in the pelvis due to different fillings of the bladder and the bowel. Consequently, large safety margins are required to compensate for organ movement, potentially leading to higher toxicity. Lately, daily high-quality cone-beam CT (CBCT) guided adaptive radiotherapy, aided by artificial intelligence (AI), became clinically available. Due to the improved soft-tissue contrast, the treatment plan can now be online adapted to the current position of the tumor and the adjacent organs-at-risk (OAR), while the patient is lying on the treatment couch. Moreover, the German Research Cancer Center offers the unique possibility of additional weekly magnetic resonance imaging (MRI) in treatment position using a shuttle system. Daily CBCT-adapted EBRT in combination with weekly MRI in treatment position might therefore offer superior sparing of surrounding OAR and consequently reduction of treatment-associated side-effects. However, to the investigators knowledge, no toxicity data for daily CBCT/AI adaptive EBRT of locally advanced cervical cancer with additional MR-guidance exists. The AIM-C1 trial therefore aims to assess the potential of daily CBCT adaptive and AI aided EBRT combined with additional weekly offline MR-guidance in treatment position using a shuttle system.

NCT ID: NCT06136702 Recruiting - Cervical Cancer Clinical Trials

ELEVATE Acceptability Study

ELEVATE AS
Start date: December 7, 2022
Phase: N/A
Study type: Interventional

This study includes a community-based, two-arm prospective acceptability study, whereby arm 1 consists of an educational session on sexual health and cervical cancer (screening) and a follow-up assessment after 3 months. Arm 2 consists of an educational session on sexual health and cervical cancer (screening) and self-sampling, additionally women will be asked to take a self-sample on-site, followed by a follow-up assessment after 3 months. Attitudes, uptake and users' experiences related to the use of a HPV self-sampling test will be assessed, additionally, the impact on looking for follow up care of self-sampling with standard cervical screening strategies will be assessed and finally the feasibility of an HPV self-sampling in hard-to-reach groups versus educational sessions and standard care will be compared (arm 1 and 2).